New hope for bladder cancer patients: experimental drug boosts standard treatment
NCT ID NCT07207824
Summary
This study is testing whether adding a new targeted drug called disitamab vedotin to the standard BCG treatment works better for people with early-stage, high-risk bladder cancer. About 182 participants will be randomly assigned to receive either the standard BCG treatment alone or BCG plus the new drug. The goal is to see if the combination helps keep the cancer from coming back or getting worse for longer than the standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200230, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.